Literature DB >> 30346411

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery.

Sigrid S Skånland1.   

Abstract

Aberrant cell signaling plays a central role in cancer development and progression. Most novel targeted therapies are indeed directed at proteins and protein functions, and cell signaling aberrations may therefore serve as biomarkers to indicate personalized treatment options. As opposed to DNA and RNA analyses, changes in protein activity can more efficiently evaluate the mechanisms underlying drug sensitivity and resistance. Phospho flow cytometry is a powerful technique that measures protein phosphorylation events at the cellular level, an important feature that distinguishes this method from other antibody-based approaches. The method allows for simultaneous analysis of multiple signaling proteins. In combination with fluorescent cell barcoding, larger medium- to high-throughput data-sets can be acquired by standard cytometer hardware in short time. Phospho flow cytometry has applications both in studies of basic biology and in clinical research, including signaling analysis, biomarker discovery and assessment of pharmacodynamics. Here, a detailed experimental protocol is provided for phospho flow analysis of purified peripheral blood mononuclear cells, using chronic lymphocytic leukemia cells as an example.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30346411      PMCID: PMC6235416          DOI: 10.3791/58386

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  19 in total

1.  Phosphoprotein Detection by High-Throughput Flow Cytometry.

Authors:  Johannes Landskron; Kjetil Taskén
Journal:  Methods Mol Biol       Date:  2016

2.  Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling.

Authors:  Peter O Krutzik; Garry P Nolan
Journal:  Nat Methods       Date:  2006-05       Impact factor: 28.547

Review 3.  Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

4.  Single cell phospho-specific flow cytometry can detect dynamic changes of phospho-Stat1 level in lung cancer cells.

Authors:  Chien-Chung Lin; Wei-Lun Huang; Wen-Pin Su; Helen H W Chen; Wu-Wei Lai; Jing-Jou Yan; Wu-Chou Su
Journal:  Cytometry A       Date:  2010-11       Impact factor: 4.355

5.  Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells.

Authors:  Jürgen Pollheimer; Johanna Bodin; Olav Sundnes; Reidunn J Edelmann; Sigrid S Skånland; Jon Sponheim; Mari Johanna Brox; Eirik Sundlisaeter; Tamara Loos; Morten Vatn; Monika Kasprzycka; Junbai Wang; Axel M Küchler; Kjetil Taskén; Guttorm Haraldsen; Johanna Hol
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

6.  Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks.

Authors:  Alan J Simmons; Cherié R Scurrah; Eliot T McKinley; Charles A Herring; Jonathan M Irish; M Kay Washington; Robert J Coffey; Ken S Lau
Journal:  Sci Signal       Date:  2016-10-11       Impact factor: 8.192

7.  Single cell profiling of potentiated phospho-protein networks in cancer cells.

Authors:  Jonathan M Irish; Randi Hovland; Peter O Krutzik; Omar D Perez; Øystein Bruserud; Bjørn T Gjertsen; Garry P Nolan
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

8.  Cytometry-based single-cell analysis of intact epithelial signaling reveals MAPK activation divergent from TNF-α-induced apoptosis in vivo.

Authors:  Alan J Simmons; Amrita Banerjee; Eliot T McKinley; Cherie' R Scurrah; Charles A Herring; Leslie S Gewin; Ryota Masuzaki; Seth J Karp; Jeffrey L Franklin; Michael J Gerdes; Jonathan M Irish; Robert J Coffey; Ken S Lau
Journal:  Mol Syst Biol       Date:  2015-10-30       Impact factor: 11.429

9.  Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia.

Authors:  Ida K Myhrvold; Andrea Cremaschi; Johanne U Hermansen; Geir E Tjønnfjord; Ludvig A Munthe; Kjetil Taskén; Sigrid S Skånland
Journal:  Oncotarget       Date:  2018-01-04

10.  Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Authors:  Egil S Blix; Jonathan M Irish; Anne Husebekk; Jan Delabie; Lise Forfang; Anne M Tierens; June H Myklebust; Arne Kolstad
Journal:  BMC Cancer       Date:  2012-10-16       Impact factor: 4.430

View more
  6 in total

1.  Cryopreservation of primary B cells minimally influences their signaling responses.

Authors:  Johanne U Hermansen; Geir E Tjønnfjord; Ludvig A Munthe; Kjetil Taskén; Sigrid S Skånland
Journal:  Sci Rep       Date:  2018-12-05       Impact factor: 4.379

2.  Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.

Authors:  Katrine Melvold; Mariaserena Giliberto; Linda Karlsen; Pilar Ayuda-Durán; Robert Hanes; Toril Holien; Jorrit Enserink; Jennifer R Brown; Geir E Tjønnfjord; Kjetil Taskén; Sigrid S Skånland
Journal:  Mol Oncol       Date:  2021-12-18       Impact factor: 6.603

3.  Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically.

Authors:  Mariaserena Giliberto; Deepak B Thimiri Govinda Raj; Andrea Cremaschi; Sigrid S Skånland; Alexandra Gade; Geir E Tjønnfjord; Fredrik Schjesvold; Ludvig A Munthe; Kjetil Taskén
Journal:  Mol Oncol       Date:  2022-03-12       Impact factor: 6.603

4.  Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case.

Authors:  Sigrid S Skånland; Marit Inngjerdingen; Henrik Bendiksen; Jamie York; Signe Spetalen; Ludvig A Munthe; Geir E Tjønnfjord
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

Review 5.  Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases.

Authors:  Yaron Ilan
Journal:  J Pers Med       Date:  2022-08-10

6.  Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.

Authors:  Marthe Jøntvedt Jørgensen; Kristin G Nore; Hans Christian D Aass; Emilie Layre; Jérôme Nigou; Rasmus Mortensen; Kjetil Tasken; Dag Kvale; Synne Jenum; Kristian Tonby; Anne Ma Dyrhol-Riise
Journal:  Front Cell Infect Microbiol       Date:  2021-07-09       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.